Peer-reviewed veterinary case report
Carvedilol added to heart treatment in dogs with mitral valve disease
By Marcondes-Santos, Mário et al.·Published in Journal of veterinary internal medicine·2007·Heart Institute (InCor), Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of carvedilol treatment in dogs with chronic mitral valvular disease.
- Species:
- dog
Plain-English summary
A group of dogs with chronic mitral valvular disease (CMVD), which can cause heart problems, were treated with either standard medications or standard medications plus carvedilol, a beta-blocker. After three months, the dogs that received carvedilol showed improvements in their quality of life and heart function scores, as well as lower blood pressure. While carvedilol didn't significantly change the heart's function measurements, it did help the dogs feel better overall. This suggests that carvedilol could be a helpful addition to treatment for dogs with CMVD.
People also search for: dog heart disease treatment · carvedilol for dogs · improving quality of life in dogs with heart problems
Abstract
BACKGROUND: Stimulation of the sympathetic nervous system occurs during the development of heart failure in dogs with chronic mitral valvular disease (CMVD). HYPOTHESIS: The use of beta-blockers to modulate the activation of the sympathetic nervous system would be useful in dogs with CMVD. ANIMALS: Group A included 13 dogs who received the conventional treatment (digoxin, benazepril, a reduced sodium diet, and codeine, and a diuretic when indicated), and group B included 12 dogs who received the protocol above plus carvedilol (0.3 mg/kg q12h). METHODS: Blinded, placebo, controlled study. RESULTS: The main echodopplercardiographic variables, heart rate, biochemical data, functional classification (FC) (New York Heart Association) and quality of life score (functional evaluation of cardiac health questionnaire) were assessed at baseline (TO) and after 3 months (T1). Only group B showed improvement in score of quality of life (13.8 +/- 8.8 versus 6.0 +/- 6.3; P < .001), in FC (2.4 - 0.9 versus 1.8 +/- 0.7; P = .032) and a reduction in systolic blood pressure (151.2 +/- 18.3 versus 124.5 +/- 23.4; P = .021). Two deaths from group A and 1 from B were related to CMVD. CONCLUSION: The studied dose of carvedilol in this group did not improve the sympathetic activation and echocardiographic variables over 3 months of chronic oral treatment. However, the results suggested a beneficial effect on the quality of life score, functional classification, and a reduction on systolic blood pressure.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17939555/